MJMaria Juachon

Maria Juachon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Juachon has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcranial Magnetic Stimulation as a Translational Biomarker in Early‐Phase Anti‐Seizure Medication Development: A Randomized, Double‐Blind, Placebo‐Controlled Study in Generalized Epilepsy

    by Catherine M. E. de Cuba, Titia Q. Ruijs, Annika A. de Goede, Robert J. Doll, Maria Juachon, Michel J. A. M. van Putten, Geert Jan Groeneveld, Jules A. A. C. Heuberger

    One‐third of epilepsy patients remain treatment‐resistant, underscoring the need for novel anti‐seizure medications (ASMs) and reliable biomarkers of central target engagement. Cortical hyperexcitability is a hallmark of epilepsy, making excitability a valuable pharmacodynamic biomarker for early‐phase drug development supporting go/no‐go decision making. Building upon prior transcranial magnetic stimulation (TMS) work in healthy participants, this study aimed to establish TMS‐derived endpoints as translational biomarkers of ASM effects in patients. In a randomized, double‐blind, placebo‐controlled, two‐way crossover design, patients with generalized epilepsy on levetiracetam (500 mg twice daily; n = 14) or valproic acid (≤1,000 mg/day; levetiracetam‐naïve, n = 12) received a single oral dose of levetiracetam (2000 mg) or placebo. Participants were asked to refrain from their morning ASM dose to minimize background ASM levels while maintaining seizure protection. TMS combined with electromyography (EMG) and electroencephalography (EEG), and resting‐state EEG were performed pre‐dose, 1.5 h, and 3 h post‐dose. Outcomes were analyzed using mixed‐effects analysis of covariance or cluster‐based permutation testing. Levetiracetam significantly reduced motor‐evoked potential (MEP) amplitude, enhanced long‐interval intracortical inhibition (LICI), and increased frontal gamma and beta power, with larger effect sizes in levetiracetam‐naïve patients. These findings were further supported by linear concentration–response relationships for these endpoints. TMS–EEG revealed group‐specific modulation: early TMS‐evoked potential components (P30/N45) in levetiracetam patients vs. later components (N100/P180) in levetiracetam‐naïve patients. These findings build upon prior results, demonstrating that TMS‐based biomarkers are sensitive to levetiracetam's acute effects in epilepsy patients with MEP amplitude, LICI, and frontal beta/gamma power emerging as promising biomarkers, possible also for new ASM development.


  • Open Access

    Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

    by Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, et al.

    Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions. We hypothesized that the intravenous LPS challenge model could be implemented in oncology drug studies in healthy participants to evaluate in vivo pharmacodynamics of new drugs. This open‐label study included 13 healthy males who received a single intravenous dose of 1 or 2 ng/kg LPS. Blood and bone marrow samples were collected pre‐ and post‐LPS for bulk RNA sequencing, multiplex cytokine measurements, immunophenotyping, and immunohistochemistry of bone marrow biopsies. Differentially expressed genes were integrated with the OpenTargets Platform and the COSMIC database to assess their tractability and relation to cancer hallmarks. The LPS challenge and bone marrow sampling were safe and well tolerated. In peripheral blood, LPS induced a rapid, transient inflammatory response, with myeloid cell activation and enrichment of inflammation‐related pathways. Conversely, bone marrow showed an attenuated cellular response and activation of hematopoietic and cell cycle‐related transcriptional programs. We identified 91 LPS‐induced oncology‐relevant targets in blood and 24 targets in bone marrow. The oncogenic transcription factor MYC was upregulated in the bone marrow, which was confirmed at the protein level by a dose‐dependent increase in c‐Myc expression. Our findings highlight the potential of immune challenges in healthy participants to pharmacodynamically profile novel oncology agents, with the aim of generating early pharmacological data ahead of pivotal clinical trials in cancer patients.

  • Open Access

    CB1 Receptor Antagonist Selonabant (ANEB‐001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial

    by Andriy A. Gorbenko, Jules A. A. C. Heuberger, Maria Juachon, Erica Klaassen, Michael Tagen, Joseph F. Lawler, Daniel Schneeberger, Kenneth C. Cundy, Linda E. Klumpers, Geert J. Groeneveld

    Emergency department visits due to cannabinoid‐induced toxicity, including acute cannabinoid intoxication (ACI) have increased worldwide as more states have liberalized cannabis policy. ACI symptoms include anxiety, panic attacks, tachycardia, and psychosis, primarily mediated through cannabinoid type 1 receptor (CB1) agonism by Δ9‐tetrahydrocannabinol (THC). This phase II randomized, double‐blind, placebo‐controlled study assessed the potential of CB1 receptor antagonist selonabant (ANEB‐001) to block THC‐induced effects in healthy adults. In Part A of the study, 10.5 mg of THC was coadministered with 50 mg (N = 20) or 100 mg (N = 20) selonabant, or matching placebo (N = 20). In Part B, 21‐mg THC was coadministered with 30 mg (N = 9) or 10 mg (N = 7) selonabant, or matching placebo (N = 9). THC‐related effects were assessed using visual analogue scales (VAS) for feeling high and alertness, objective measures of postural stability, and heart rate and analyzed using a mixed effects model. Selonabant significantly reduced VAS “Feeling High” (up to −82.8% (95% CI: −91.0%, −67.2%, P < 0.0001) at 30‐mg selonabant) and increased VAS “Alertness” (up to 10.8 mm (95% CI: 4.7, 16.8 mm, P = 0.001) at 30‐mg selonabant) vs. placebo. Selonabant 10 and 30 mg significantly reduced body sway (up to −30.6% (95% CI: −44.1%, −13.9%, P = 0.002) at 30 mg selonabant) vs. placebo. Effects on heart rate were not significant. Selonabant was generally safe and no clinically meaningful changes in mood occurred. Nausea and vomiting occurred more frequently at high selonabant doses; 10‐mg selonabant was both well tolerated and efficacious. Present results support further development of selonabant for emergency treatment of ACI.